Main > ONCOLOGY (**) > Mesothelioma>Pleural>Malignant > TREAT.: > USA. B. NivoluMAb+IpilimuMAb



USA. B. NivoluMAb+IpilimuMAb's subsections
(*) USA Approval Date: 2020. 10.02
Company
Patent>Assignee; Claims; No.; Etc.
PR Web-Site
TradeMark

USA. B. NivoluMAb+IpilimuMAb's products
This section has no products